Home > Insider Trading > Filing (0001104659-14-082116)

Filing Details

Accession Number:: 0001104659-14-082116
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-19 19:23:28
Reporting Period:: 2014-11-17

Filing Date:: 2014-11-19
Accepted Time:: 2014-11-19 19:23:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192128	M Luke Beshar	550 Hills Drive Bedminster NJ 07921	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-11-17	4,848	$5.85	77,628	No	4	M	Direct
Common Stock	Acquisiton	2014-11-17	31,812	$3.34	109,440	No	4	M	Direct
Common Stock	Acquisiton	2014-11-17	10,782	$8.25	120,222	No	4	M	Direct
Common Stock	Disposition	2014-11-17	47,442	$30.01	72,780	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Options (right to buy)	Disposition	2014-11-17	4,848	$0.00	4,848	$5.85
Common Stock	Employee Stock Options (right to buy)	Disposition	2014-11-17	31,812	$0.00	27,499	$3.34
Common Stock	Employee Stock Options (right to buy)	Disposition	2014-11-17	10,782	$0.00	10,782	$8.25

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-02-15	No	4	M	Direct
20,689	2020-02-19	No	4	M	Direct
7,188	2021-02-17	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.105, inclusive. The Reporting Person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
On October 15, 2008, the Reporting Person received a grant of 12,310 stock options under the Issuer's 1998 Stock Option Plan. The options became exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter. As of the date of this filing, all 12,310 stock options have vested.
On February 19, 2010, the Reporting Person received a grant of 40,000 stock options under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 31,812 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
On February 17, 2011, the Reporting Person received a grant of 57,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.